viewMotif Bio PLC

Motif Bio presents new iclaprim data at industry conference in California

Motif presented three new posters, tackling iclaprim’s dosage, the diversity of patients who have taken part in clinical trials, and the antibiotic’s ability to fight off drug-resistant bacteria

The ASM is one of the largest life sciences societies in the world

Motif Bio PLC (LON:MTFB) has released new data for its iclaprim antibiotic at a major industry conference in San Francisco, California.

The AIM- and Nasdaq-listed biopharma presented three posters at the American Society for Microbiology (ASM) Microbe 2019 meeting over the weekend.

READ: US drugs regulator encourages Motif to carry further icalprim study

The first presentation focused on dosage, with data showing that the 80mg fixed doses given to patients in the most recent REVIVE phase III trial were more efficacious than the weight-based doses given in earlier studies.

“The fixed dose regimen may help reduce the resources required in hospitals, since dosage adjustment by clinicians is avoided, and overall treatment costs may be lower, especially in patients with obesity or renal impairment,” said Motif.

A second poster highlighted the diverse patient population in the REVIVE and earlier ASSIST phase III studies.

In total, 1,093 patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) were treated with icplarim in the studies, with older patients and those with co-morbidities such as obesity, diabetes and renal impairment were “well-represented”.

In the REVIVE and ASSIST trials, respectively:  12% and 16% of patients treated with iclaprim were 65 or older; 15% and 8% were obese; 9% and 12% had diabetes; and 15% and 41% had renal impairment.

Antibiotic resistance a major global issue

In the third poster, Motif showed off iclaprim’s “potent activity” against various Gram-positive multi-drug resistant streptococci – the bacteria that can cause disorders such as pneumonia.

Streptococci is known for its resistance to azithromycin, clindamycin and tetracycline – three of the most common antibiotics currently used to fight bacterial infections.

“Given the growing public health concern about antibiotic resistance, it is important to continue to monitor the activity of iclaprim against these bacteria,” Motif added.

Quick facts: Motif Bio PLC

Price: 0.5 GBX

Market: AIM
Market Cap: £3.27 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Bango reports record revenue growth in the first half of 2020

Bango PLC's (LON:BGO) Paul Larbey talks to Proactive's Katie Pilbeam `about their latest record revenue growth in the first half of this year. Larbey is confident Bango is positioned to continue delivering growth after reporting revenues of £4.77mln, up 50% year-on-year. He goes on to...

1 hour, 53 minutes ago

2 min read